Free Trial
NASDAQ:INDP

Indaptus Therapeutics (INDP) Stock Price, News & Analysis

Indaptus Therapeutics logo
$2.52 +0.15 (+6.33%)
As of 01:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Indaptus Therapeutics Stock (NASDAQ:INDP)

Advanced

Key Stats

Today's Range
$2.31
$2.59
50-Day Range
$2.28
$12.58
52-Week Range
$2.22
$58.24
Volume
226,547 shs
Average Volume
115,091 shs
Market Capitalization
$2.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$238.00
Consensus Rating
Buy

Company Overview

Indaptus Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

INDP MarketRank™: 

Indaptus Therapeutics scored higher than 69% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Indaptus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Indaptus Therapeutics has a consensus price target of $238.00, representing about 9,674.1% upside from its current price of $2.44.

  • Amount of Analyst Coverage

    Indaptus Therapeutics has received no research coverage in the past 90 days.

  • Read more about Indaptus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Indaptus Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Indaptus Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Indaptus Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Indaptus Therapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Indaptus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.51% of the float of Indaptus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Indaptus Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Indaptus Therapeutics has recently decreased by 19.25%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Indaptus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Indaptus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.51% of the float of Indaptus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Indaptus Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Indaptus Therapeutics has recently decreased by 19.25%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Indaptus Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • MarketBeat Follows

    2 people have added Indaptus Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    20.80% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.06% of the stock of Indaptus Therapeutics is held by institutions.

  • Read more about Indaptus Therapeutics' insider trading history.
Receive INDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INDP Stock News Headlines

Crypto Gets Official Government Backing—Here's the Winner
Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really investing in this coin.tc pixel
Indaptus Therapeutics Provides Clinical Update
See More Headlines

INDP Stock Analysis - Frequently Asked Questions

Indaptus Therapeutics' stock was trading at $23.5788 at the start of the year. Since then, INDP stock has decreased by 89.7% and is now trading at $2.4350.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced its quarterly earnings data on Wednesday, August, 13th. The company reported ($9.09) EPS for the quarter, missing the consensus estimate of ($0.36) by $8.73.

Indaptus Therapeutics shares reverse split on Friday, June 27th 2025.A 1-28 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 26th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Indaptus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), GE Aerospace (GE), Meta Platforms (META), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/13/2025
Today
9/18/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INDP
CIK
1857044
Employees
6
Year Founded
N/A

Price Target and Rating

High Price Target
$336.00
Low Price Target
$140.00
Potential Upside/Downside
+9,942.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($37.66)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.02 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-612.59%
Return on Assets
-243.78%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.75
Quick Ratio
0.75

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.84 per share
Price / Book
0.22

Miscellaneous

Outstanding Shares
1,110,000
Free Float
877,000
Market Cap
$2.63 million
Optionable
Not Optionable
Beta
1.27
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:INDP) was last updated on 9/18/2025 by MarketBeat.com Staff
From Our Partners